It looks like a lot of investors aren’t sure what to do these days, with the stock market gyrating widely as a result of the Fed’s interest rate hike last week. But that’s okay with us, since heightened volatility has a tendency to create buying opportunities in companies that all “get painted with the same brush” of doubt and uncertainty. At STI we like to think that we paint with a different type of brush, one that stays steady and knows where to find value while everyone else is running scared.

In this issue you will find a new bio-med stock recommendation from Dr. Joe Duarte in his In Focus article, featuring a company that nearly rates a perfect score according to his EBIS stock rating system. Its rare that his model scores any stock a ‘9’ on his scale of 0 – 11 (that’s right all you Spinal Tap fans out there, his scale goes to 11!), so this is one to take note of.

In his Sector Spotlight article, Rob DeFrancesco looks at two players in the fast growing field of mobile apps, one of which is a current recommendation, and the other a potential future holding. And in his Portfolio Update, Rob is adding another stock to the Next Wave Portfolio, this one in cloud software.

Also, a heads up about next week’s issue of Smart Tech 50 Weekly Movers. Over the past several months we have featured articles from Linda McDonough, who has developed a revolutionary system for identifying stocks from all sectors about to explode to the upside. We are so impressed with the profit-making potential of her system that Investing Daily will be launching an entirely new service build around it in January. However, she is going to share one of her very first portfolio recommendations with the readers of STI next week, so be sure to take a look at this issue since you will have an “early mover” advantage over the rest of our subscribers to get in on this stock before everyone else is told about it.

Speaking of stocks exploding to the upside, you may have noticed the huge jump last week by Medical Profits Portfolio holding ReWalk Bionics, which we first recommended back in June as part of a trio of stocks as a diversified play on exoskeleton technology. At that time the stock was trading between $11 – 12 per share, and since then had steadily drifted downward to less than $6 last week. But that all changed in the blink of eye after the company announced on Thursday it had reached an agreement with the U.S. Department of Veteran Affairs for it to pay for some of the company’s exoskeleton products to treat wounded warriors. We think this bodes well not only for RWLK, but should open the door wider for greater acceptance of this type of technology for a variety of medical conditions.